Health · Full coverage
New Drug Ensitrelvir Shows Promise in Preventing COVID-19 Infection After Exposure
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
100% center
Center 2
First reported by Mako · 6 hours ago
What happened
A new study shows that the antiviral drug Ensitrelvir can prevent COVID-19 infection in people exposed to the virus, reducing infection risk by over two-thirds. Approved in Japan and recently by the FDA in the U.S., the drug disrupts viral replication and delays symptom onset, offering a new preventive option beyond vaccines.
- 01Ensitrelvir reduces COVID-19 infection risk by over two-thirds after exposure.
- 02The drug delays symptom onset in those who still become infected.
- 03Clinical trials involved 1,000 participants across five countries from 2023 to 2024.
- 04Ensitrelvir inhibits a viral enzyme essential for virus replication.
- 05FDA approved Ensitrelvir for COVID-19 prevention in June 2026.
- 06No significant side effects were reported in the study.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
AI-Developed Psoriasis Drug Outperforms Leading Treatment in Phase 3 TrialJun 30, 2026Teva Reports Positive Phase 1b Results for Vitiligo Antibody, Plans Phase 2b in 20262 days agoFDA Approves First Dual-Action Drug for IgA Nephropathy Kidney Disease6 hours agoAustralian Scientists Develop Plastic Film That Kills 94% of Viruses on Contact4 days agoCancer Vaccine Shows Promise, Leaving One Patient Disease-Free for More Than Six YearsJun 11, 2026Experimental Weight-Loss Drug Gains Attention Amid Trump Usage RumorsJun 28, 2026
